Skip to main content

Table 1 PARI LC Nebulizer MADD via Impactor for Nanosuspension on Different Dose Range

From: Evaluation of Aerosol Delivery of Nanosuspension for Pre-clinical Pulmonary Drug Delivery

Formulation Concentration (mg/mL) Duration (min) MMAD (μm)
21.74 2.0 3.6
4.35 4.0 4.1
2.44 4.0 3.5
0.43 8.0 3.9
0.04 8.0 3.4
   Average 3.7 ± 0.3